SEC-sourced researchBeta
ELOX
Eloxx Pharmaceuticals, Inc.
Company comparison ↗
Data passport
- CIK
- 0001035354
- Exchange
- Nasdaq
- Business activity
- — · SIC 2836
- Financial inputs
- 6/6
- Filing date
- Sep 18, 2026
- SEC registry record
- Operating company
Annual financial history
Up to three published annual periods. The chart shows financial statement amounts; missing observations are not connected. Each company chart uses its own scale; compare amounts in the table.
| Period end | Revenue | Filing date |
|---|---|---|
| December 2023 | 0.0000 | Mar 17, 2026 |
| December 2024 | 6,359,000.0000 | Mar 17, 2026 |
| December 2025 | 0.0000 | Mar 17, 2026 |
Annual periods · USD
| Period end | Revenue | Net income | Operating cash flow | Total assets | Total liabilities | Filing date |
|---|---|---|---|---|---|---|
| December 2025 | 0.0000 | -5,995,000.0000 | -6,327,000.0000 | 5,270,000.0000 | 17,177,000.0000 | Mar 17, 2026 |
| December 2024 | 6,359,000.0000 | -3,143,000.0000 | -4,715,000.0000 | 2,976,000.0000 | 27,311,000.0000 | Mar 17, 2026 |
| December 2023 | 0.0000 | -17,054,000.0000 | -14,341,000.0000 | 1,712,000.0000 | 24,311,000.0000 | Mar 17, 2026 |
Financial inputs behind the calculation
| Financial inputs | USD | Period end | Filing date | Form |
|---|---|---|---|---|
| RevenueRevenues | $0 | December 2025 | Mar 17, 2026 | 10-K |
| Previous period revenueRevenues | $6.36M | December 2024 | Mar 17, 2026 | 10-K |
| Net incomeNetIncomeLoss | -$6M | December 2025 | Mar 17, 2026 | 10-K |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | -$6.33M | December 2025 | Mar 17, 2026 | 10-K |
| Total assetsAssets | $5.27M | December 2025 | Mar 17, 2026 | 10-K |
| Total liabilitiesLiabilities | $17.18M | December 2025 | Mar 17, 2026 | 10-K |